Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REG1 Anticoagulation System in Acute Coronary Syndrome
NCT00932100Phase 2Completed
- Sponsor
- Regado Biosciences
- Start
- Jul 2009
- Primary completion
- Jan 2011
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 4
01
Overview
Phase 2, randomised, single-blind trial of pegnivacogin in acute coronary syndrome (ACS) (5 arms), sponsored by Regado Biosciences. Primary endpoint: The composite incidence of major and minor bleeding at 30 days. Started Jul 2009; status: completed.
02
Drugs
pegnivacogin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00932100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932100.